Anzupgo

News

LEO launches chronic hand eczema drug in its first market

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE).

News

physician holds hand of a person with chronic hand eczema

LEO closes on first approval for chronic hand eczema drug

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

News

Trodelvy gets EU nod for first-line triple-neg breast cancer

A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks